Patents Assigned to SUZHOU PENGXU PHARMATECH CO., LTD.
-
Patent number: 11926633Abstract: The present disclosure relates to a JAK inhibitor upadacitinib intermediate and a preparation method therefor, and to a preparation method for a JAK inhibitor upadacitinib. The upadacitinib intermediate of the present application is as shown in Formula (II) or Formula (III), wherein, R is a protective group of nitrogen atoms, and R1 is an open-chain or cyclic amine group. Compared with the prior art, the method for the synthesis of upadacitinib of the present application, significantly reduces cost, is environmentally-friendly. And the quality of the final product is well controlled.Type: GrantFiled: August 26, 2019Date of Patent: March 12, 2024Assignee: SUZHOU PENGXU PHARMATECH CO., LTDInventors: Peng Wang, Pixu Li, Qiang Wei, Wen Cheng, Hao Wu
-
Publication number: 20230183180Abstract: A process of making Roxadustat of the following formula: comprising converting a compound of formula VI: to Roxadustat, wherein R is a C1-C20 alkyl group, and PG is a protective group.Type: ApplicationFiled: June 4, 2021Publication date: June 15, 2023Applicant: SUZHOU PENGXU PHARMATECH CO., LTD.Inventors: Peng WANG, Pixu LI, Hailong YANG, Qiang WEI
-
Patent number: 11673862Abstract: The present invention provides a scalable synthesis of enantiomerically pure brivaracetam, and related derivatives.Type: GrantFiled: January 24, 2019Date of Patent: June 13, 2023Assignee: SUZHOU PENGXU PHARMATECH CO. LTD.Inventors: Peng Wang, Pixu Li, Qiang Wei, Yuanhua Liu
-
Patent number: 11377426Abstract: The present invention relates to a scalable process for the making of elagolix, its salts and the process of intermediate compounds.Type: GrantFiled: December 3, 2018Date of Patent: July 5, 2022Assignee: SUZHOU PENGXU PHARMATECH CO., LTD.Inventors: Pixu Li, Peng Wang, Xiangyong Gu, Hailong Yang, Zhong Wang, Qianghua Jiang, Yuanhua Liu, Hui Xia
-
Patent number: 11161851Abstract: The present invention relates to a method for preparing the compound of formula IV, compound of formula XI, and acalabrutinib, a new generation of bruton tyrosine kinase (BTK) inhibitor.Type: GrantFiled: November 5, 2018Date of Patent: November 2, 2021Assignee: Suzhou PengXu Pharmatech Co. Ltd.Inventors: Peng Wang, Pixu Li, Xiangyong Gu, Yadong Ge, Zhong Wang, Feng Gao, Qiangqiang Du
-
Publication number: 20210214318Abstract: The present invention relates to a scalable process for the making of elagolix, its salts and the process of intermediate compounds.Type: ApplicationFiled: December 3, 2018Publication date: July 15, 2021Applicant: SUZHOU PENGXU PHARMATECH CO., LTD.Inventors: Pixu LI, Peng WANG, Xiangyong GU, Hailong YANG, Zhong WANG, Qianghua JIANG, Yuanhua LIU, Hui XIA
-
Publication number: 20200354368Abstract: The present invention relates to a method for preparing the compound of formula IV, compound of formula XI, and acalabrutinib, a new generation of bruton tyrosine kinase (BTK) inhibitor.Type: ApplicationFiled: November 5, 2018Publication date: November 12, 2020Applicant: SUZHOU PENGXU PHARMATECH CO., LTD.Inventors: Peng WANG, Pixu LI, Xiangyong GU, Yadong GE, Zhong WANG, Feng GAO, Qiangqiang DU
-
Patent number: 10508087Abstract: Novel crystalline forms of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate-(S)-3?-methyl-2?-(pentanoyl{2?-(tetrazol-5-ylate)biphenyl-4?-ylmethyl}amino)butyrate] hydrate, methods for their preparation, pharmaceutical compositions comprising these new forms, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of angiotensin receptor 1 (AT1) blockage and neprilysin (NEP) inhibition, such as heart failure, are disclosed.Type: GrantFiled: March 18, 2018Date of Patent: December 17, 2019Assignees: CRYSTAL PHARMATECH CO., LTD., SUZHOU PENGXU PHARMATECH CO., LTD.Inventors: Minhua Chen, Yanfeng Zhang, Chaohui Yang, Xiaoyu Zhang
-
Patent number: 10351536Abstract: Novel crystalline forms of lesinurad and its sodium salt, processes for their preparation, pharmaceutical compositions comprising these new forms, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of uric acid transporter 1 (URAT1) proteins are disclosed. These novel forms were characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. They can be readily prepared and are suitable for preparation of solid dosage forms owing to their ease of handling and superior pharmacological properties.Type: GrantFiled: November 20, 2014Date of Patent: July 16, 2019Assignees: Crystal Pharmatech Co., Ltd., Suzhou Pengxu Pharmatech Co., Ltd.Inventors: Minhua Chen, Yanfeng Zhang, Chaohui Yang, Xiaoyu Zhang, Peng Wang, Pixu Li
-
Patent number: 9969701Abstract: Novel salts and cocrystals of lesinurad, processes for their preparation, pharmaceutical compositions comprising these new salt forms and co-crystals, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of uric acid transport 1 (URAT1) proteins are disclosed. These novel forms were characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. They can be readily prepared and are suitable for preparation of solid dosage forms owing to their ease of handling and superior pharmacological properties.Type: GrantFiled: December 19, 2014Date of Patent: May 15, 2018Assignees: Crystal Pharmatech Co., Ltd., Suzhou Pengxu Pharmatech Co., Ltd.Inventors: Minhua Chen, Yanfeng Zhang, Chaohui Yang, Xiaoyu Zhang, Peng Wang, Pixu Li
-
Patent number: 9957240Abstract: Novel crystalline Forms of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butyl carbamoyl) propionate-(S)-3?-methyl-T-(pentanoyl{2?-(tetrazol-5-ylate)biphenyl-4?-ylmethyl}amino)butyrate] hydrate, methods for their preparation, pharmaceutical compositions comprising these new forms, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of angiotensin receptor 1 (AT1) blockage and neprilysin (NEP) inhibition, such as heart failure, are disclosed.Type: GrantFiled: December 8, 2015Date of Patent: May 1, 2018Assignees: CRYSTAL PHARMATECH CO., LTD, SUZHOU PENGXU PHARMATECH CO., LTD.Inventors: Minhua Chen, Yanfeng Zhang, Chaohui Yang, Xiaoyu Zhang, Jiaoyang Li, Peng Wang, Pixu Li
-
Publication number: 20170362189Abstract: Novel crystalline Forms of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butyl carbamoyl) propionate-(S)-3?-methyl-T-(pentanoyl{2?-(tetrazol-5-ylate)biphenyl-4?-ylmethyl}amino)butyrate] hydrate, methods for their preparation, pharmaceutical compositions comprising these new forms, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of angiotensin receptor 1 (AT1) blockage and neprilysin (NEP) inhibition, such as heart failure, are disclosed.Type: ApplicationFiled: December 8, 2015Publication date: December 21, 2017Applicants: CRYSTAL PHARMATECH CO., LTD, SUZHOU PENGXU PHARMATECH CO., LTD.Inventors: Minhua CHEN, Yanfeng ZHANG, Chaohui YANG, Xiaoyu ZHANG, Jiaoyang LI, Peng WANG, Pixu LI
-
Patent number: 9751889Abstract: Crystalline Form I of ibrutinib, processes for its preparation, pharmaceutical compositions comprising the new Form, and use of Form I of ibrutinib for treating or delaying diseases or disorders related to activity of Bruton's tyrosine kinase (BTK) proteins are disclosed. The novel Form was characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. It can be readily prepared and is suitable for use in the preparation of solid dosage forms.Type: GrantFiled: November 26, 2014Date of Patent: September 5, 2017Assignees: Crystal Pharmatech Inc., Suzhou Pengxu Pharmatech Co., Ltd.Inventors: Minhua Chen, Yanfeng Zhang, Chaohui Yang, Xiaoyu Zhang, Peng Wang, Pixu Li, Fei Lu, Heng Ge
-
Publication number: 20170002009Abstract: Crystalline Form I of ibrutinib, processes for its preparation, pharmaceutical compositions comprising the new Form, and use of Form I of ibrutinib for treating or delaying diseases or disorders related to activity of Bruton's tyrosine kinase (BTK) proteins are disclosed. The novel Form was characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. It can be readily prepared and is suitable for use in the preparation of solid dosage forms.Type: ApplicationFiled: November 26, 2014Publication date: January 5, 2017Applicants: CRYSTAL PHARMATECH INC., SUZHOU PENGXU PHARMATECH CO., LTD.Inventors: Minhua CHEN, Yanfeng ZHANG, Chaohui YANG, Xiaoyu ZHANG, Peng WANG, Pixu LI, Fei LU, Heng GE
-
Publication number: 20160347722Abstract: Novel salts and cocrystals of lesinurad, processes for their preparation, pharmaceutical compositions comprising these new salt forms and co-crystals, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of uric acid transport 1 (URAT1) proteins are disclosed. These novel forms were characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. They can be readily prepared and are suitable for preparation of solid dosage forms owing to their ease of handling and superior pharmacological properties.Type: ApplicationFiled: December 19, 2014Publication date: December 1, 2016Applicants: CRYSTAL PHARMATECH CO., LTD., SUZHOU PENGXU PHARMATECH CO., LTD.Inventors: Minhua CHEN, Yanfeng ZHANG, Chaohui YANG, Xiaoyu ZHANG, Peng WANG, Pixu LI
-
Publication number: 20160297778Abstract: Novel crystalline forms of lesinurad and its sodium salt, processes for their preparation, pharmaceutical compositions comprising these new forms, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of uric acid transporter 1 (URAT1) proteins are disclosed. These novel forms were characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. They can be readily prepared and are suitable for preparation of solid dosage forms owing to their ease of handling and superior pharmacological properties.Type: ApplicationFiled: November 20, 2014Publication date: October 13, 2016Applicants: CRYSTAL PHARMATECH CO., LTD, SUZHOU PENGXU PHARMATECH CO., LTD.Inventors: Minhua CHEN, Yanfeng ZHANG, Chaohui YANG, Xiaoyu ZHANG, Peng WANG, Pixu LI